CPRIT awarded more than $49 million to Texas institutions for cancer research and prevention
On Aug. 16, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had approved over…
On Aug. 16, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had approved over…
On May 9, 2023, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
On May 1, 2023, an Oregon Health Sciences University (OHSU) dermatologist and a multi-disciplinary team confirmed that a…
On Apr. 18, 2023, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening…
On Mar. 23, 2023, the Fred Hutchinson Cancer Center (FHCRC) announced a new building in South Lake Union…
On Mar. 9, 2023, the U.S. Food and Drug Administration (FDA) announced that it had published updates to…
On Feb. 15, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced a major step forward…
On Feb. 3, 2023, the World Health Organization (WHO) released an updated Global Breast Cancer Initiative (GBCI) Framework…
On Jan. 6, 2023, the Purdue Center for Cancer Research announced it was changing its name to the…
On Dec. 24, 2022, the U.S. Food and Drug Administration (FDA) approved updated labeling for Genentech’s capecitabine tablets…
On Dec. 9, 2022, the U.S. Food and Drug Administration (FDA) approved Genentech’s atezolizumab (Tecentriq) for adult and…
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
On Oct. 27, 2022, the National Institutes of Health (NIH) announced that overall cancer death rates continued to…
On Oct. 26, 2022, the Barbara Ann Karmanos Cancer Institute announced it had completed an over 50,000-square-foot expansion…
On Sept. 8, 2022, the Fred Hutchinson Cancer Center (FHCRC) announced that Stuart and Molly Sloan had pledged…
On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Daiichi Sankyo’s Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV…
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
May 27, 2022, the National Cancer Institute (NCI) truncated the just-renewed five-year Cancer Center Support Grant held by…
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
On Oct. 26, 2021, Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it had commenced…
On Oct. 15, 2021, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Tecentriq (atezolizumab)…
On Oct. 4, 2021, the Fred & Pamela Buffett Cancer Center announced it had successfully renewed its National…
On Sept. 13, 2021, Twist Bioscience announced and Adicet Bio announced a collaboration to accelerate the discovery of…
On Sept. 6, 2021, a genomic analysis of lung cancer in people with no history of smoking has…
On Aug. 27, 2021, researchers at University of British Columbia’s (UBC) faculty of medicine and BC Cancer Research…
On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…
On Jul. 8, 2021, the National Institutes of Health (NIH) reported that the overall cancer death rates continue…